TABLE 5.
Effect of oral treatment with 4′-thioIDU on mortality of BALB/c mice inoculated intranasally with cowpox virus strain Brighton
| Day after viral inoculation and treatment (dose [mg/kg])a | Mortality
|
Day of death
|
||
|---|---|---|---|---|
| No. of mice in group that died/total no. of mice in group (%) | P value | Mean + SD | P value | |
| Day 1 | ||||
| Vehicle | 15/15 (100) | 9.8 ± 3.1 | ||
| CDV (15) | 0/15 (0) | <0.001 | ||
| 4′-ThioIDU | ||||
| 15 mg/kg | 0/15 (0) | <0.001 | ||
| 5 mg/kg | 0/15 (0) | <0.001 | ||
| 1.5 mg/kg | 0/13 (0) | <0.001 | ||
| Day 2 | ||||
| Vehicle | 15/15 (100) | <0.001 | 8.7 ± 1.9 | |
| CDV (15) | 0/15 (0) | <0.001 | ||
| 4′-ThioIDU | ||||
| 15 | 1/15 (7) | <0.001 | 18.0 | 0.09 |
| 5 | 2/15 (13) | <0.001 | 16.0 ± 2.8 | <0.05 |
| 1.5 | 0/15 (0) | <0.001 | ||
| Day 3 | ||||
| Vehicle | 14/15 (93) | 11.9 ± 2.2 | ||
| CDV (15) | 0/14 (0) | <0.001 | ||
| 4′-ThioIDU | ||||
| 15 | 1/15 (7) | <0.001 | 14.0 | NSb |
| 5 | 0/15 (0) | <0.001 | ||
| 1.5 | 2/15 (13) | <0.001 | 14.0 ± 5.7 | NS |
| Day 4 | ||||
| Vehicle | 15/15 (100) | 11.7 ± 2.3 | NS | |
| CDV (15) | 0/15 (0) | <0.001 | ||
| 4′-ThioIDU (5) | 4/15 (27) | <0.001 | 13.3 ± 1.3 | <0.05 |
| Day 5 | ||||
| Vehicle | 12/15 (80) | 14.6 ± 3.9 | ||
| CDV (15) | 4/15 (27) | 0.01 | 10.5 ± 1.9 | 0.07 |
| 4′-ThioIDU (5) | 13/15 (87) | NS | 9.8 ± 1.3 | <0.001 |
| Day 8 | ||||
| Vehicle | 15/15 (100) | 10.3 ± 1.2 | ||
| CDV (15) | 4/15 (27) | <0.001 | 12.0 ± 2.7 | NS |
| 4′-ThioIDU (5) | 15/15 (100) | NS | 9.7 ± 1.3 | NS |
a
4′-ThioIDU was suspended in vehicle (10% DMSO in 0.4% CMC) and given orally in 0.2-ml doses. CDV was prepared in sterile saline and was given i.p. in 0.1-ml doses. Animals were treated twice daily with vehicle or 4′-thioIDU for 5 days or were treated with CDV once daily beginning at 1, 2, 3, 4, or 5 days after viral inoculation.
b
NS, not significant compared to the results for the placebo-treated control.